Revvity Inc. (RVTY)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE
Market Cap: $17.24B
Last updated: Nov 17, 2026 at 11:05 AM ET
Revvity Inc. (RVTY) Earnings: Report Dates and Results
Revvity (RVTY) is expected to report earnings on Feb 1, 2027. In the quarter ended Sep 30, 2026, Revvity reported EPS of $1.38, above the $1.29 estimate. It beat the EPS estimate in each of the last 12 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
RVTY has an expected report date of Feb 1, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 2.9% below the $1.70 reported for the quarter ended Dec 31, 2025.
RVTY Earnings Call
The latest RVTY earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, RVTY beat 34, missed 4 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $728.90M, up 4.3% from $698.95M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $1.38 | $1.29 | $1.28 - $1.33 | +6.98% | Beat | +16.9% | 16 | 2 up, 0 down | Nov 3, 2026 | $728.90M |
| Jun 30, 2026 | $1.41 | $1.23 | $1.18 - $1.28 | +14.63% | Beat | +19.5% | 12 | 1 up, 2 down | Jul 27, 2026 | $729.69M |
| Mar 31, 2026 | $1.06 | $1.01 | $1.00 - $1.03 | +4.95% | Beat | +5.0% | 15 | 2 up, 2 down | May 5, 2026 | $711.12M |
| Dec 31, 2025 | $1.70 | $1.58 | $1.53 - $1.64 | +7.59% | Beat | +19.7% | 15 | 2 up, 1 down | Feb 2, 2026 | $772.06M |
| Sep 30, 2025 | $1.18 | $1.14 | $1.12 - $1.16 | +3.51% | Beat | -7.8% | 16 | 2 up, 0 down | Oct 27, 2025 | $698.95M |
| Jun 30, 2025 | $1.18 | $1.14 | $1.13 - $1.15 | +3.51% | Beat | -3.3% | 17 | 3 up, 1 down | Jul 28, 2025 | $720.28M |
| Mar 31, 2025 | $1.01 | $0.95 | $0.93 - $0.97 | +6.32% | Beat | +3.1% | 18 | 0 up, 2 down | Apr 28, 2025 | $664.76M |
| Dec 31, 2024 | $1.42 | $1.38 | $1.37 - $1.39 | +2.90% | Beat | +13.6% | 13 | 1 up, 1 down | Jan 31, 2025 | $729.37M |
| Sep 30, 2024 | $1.28 | $1.13 | $1.12 - $1.15 | +13.27% | Beat | +8.5% | 18 | 1 up, 0 down | Nov 4, 2024 | $684.05M |
| Jun 30, 2024 | $1.22 | $1.12 | $1.09 - $1.18 | +8.93% | Beat | +0.8% | 17 | 0 up, 0 down | Jul 29, 2024 | $691.68M |
| Mar 31, 2024 | $0.98 | $0.94 | $0.90 - $0.98 | +4.26% | Beat | -3.0% | 15 | 1 up, 0 down | Apr 29, 2024 | $649.92M |
| Dec 31, 2023 | $1.25 | $1.16 | $1.14 - $1.20 | +7.76% | Beat | -26.5% | 16 | 6 up, 0 down | Feb 1, 2024 | $1.37B |
| Sep 30, 2023 | $1.18 | $1.19 | $1.15 - $1.25 | -0.84% | Miss | -21.9% | 14 | 1 up, 3 down | Oct 30, 2023 | N/A |
| Jun 30, 2023 | $1.21 | $1.19 | $1.15 - $1.20 | +1.68% | Beat | -47.8% | 15 | 1 up, 0 down | Aug 1, 2023 | $709.07M |
| Mar 31, 2023 | $1.01 | $1.02 | N/A | -0.98% | Miss | -58.1% | N/A | N/A | May 11, 2023 | $674.87M |
| Dec 31, 2022 | $1.70 | $1.66 | N/A | +2.41% | Beat | -33.6% | N/A | N/A | Feb 14, 2023 | $741.21M |
| Sep 30, 2022 | $1.51 | $1.48 | N/A | +2.03% | Beat | -34.6% | N/A | N/A | Nov 8, 2022 | $711.80M |
| Jun 30, 2022 | $2.32 | $2.01 | N/A | +15.42% | Beat | -18.0% | N/A | N/A | Aug 1, 2022 | $895.64M |
| Mar 31, 2022 | $2.41 | $2.12 | N/A | +13.68% | Beat | -35.2% | N/A | N/A | May 3, 2022 | $963.16M |
| Dec 31, 2021 | $2.56 | $2.35 | N/A | +8.94% | Beat | -35.4% | N/A | N/A | Feb 1, 2022 | $430.33M |
| Sep 30, 2021 | $2.31 | $1.92 | N/A | +20.31% | Beat | +10.5% | N/A | N/A | Nov 2, 2021 | $861.32M |
| Jun 30, 2021 | $2.83 | $2.44 | N/A | +15.98% | Beat | +80.3% | N/A | N/A | Jul 26, 2021 | $1.23B |
| Mar 31, 2021 | $3.72 | $3.07 | N/A | +21.17% | Beat | +455.2% | N/A | N/A | May 4, 2021 | $1.31B |
| Dec 31, 2020 | $3.96 | $3.02 | N/A | +31.13% | Beat | +193.3% | N/A | N/A | Feb 2, 2021 | $235.09M |
| Sep 30, 2020 | $2.09 | $1.49 | N/A | +40.27% | Beat | +97.2% | N/A | N/A | Oct 28, 2020 | $964.02M |
| Jun 30, 2020 | $1.57 | $0.88 | N/A | +78.41% | Beat | +57.0% | N/A | N/A | Jul 28, 2020 | $811.72M |
| Mar 31, 2020 | $0.67 | $0.52 | N/A | +28.85% | Beat | -2.9% | N/A | N/A | May 5, 2020 | $652.40M |
| Dec 31, 2019 | $1.35 | $1.33 | N/A | +1.50% | Beat | +14.4% | N/A | N/A | Jan 27, 2020 | $805.50M |
| Sep 30, 2019 | $1.06 | $1.01 | N/A | +4.95% | Beat | +17.8% | N/A | N/A | Oct 30, 2019 | $706.92M |
| Jun 30, 2019 | $1.00 | $1.00 | N/A | 0.00% | In line | +9.9% | N/A | N/A | Jul 29, 2019 | $722.52M |
| Mar 31, 2019 | $0.69 | $0.66 | N/A | +4.55% | Beat | +9.5% | N/A | N/A | Apr 25, 2019 | $648.74M |
| Dec 31, 2018 | $1.18 | $1.16 | N/A | +1.72% | Beat | +21.6% | N/A | N/A | Mar 31, 2019 | $756.35M |
| Sep 30, 2018 | $0.90 | $0.92 | N/A | -2.17% | Miss | +23.3% | N/A | N/A | Oct 31, 2018 | $674.31M |
| Jun 30, 2018 | $0.91 | $0.86 | N/A | +5.81% | Beat | +35.8% | N/A | N/A | Aug 1, 2018 | $703.36M |
| Mar 31, 2018 | $0.63 | $0.61 | N/A | +3.28% | Beat | +14.5% | N/A | N/A | Apr 30, 2018 | $643.97M |
| Dec 31, 2017 | $0.97 | $0.94 | N/A | +3.19% | Beat | +16.9% | N/A | N/A | Mar 31, 2018 | $641.63M |
| Sep 30, 2017 | $0.73 | $0.72 | N/A | +1.39% | Beat | +7.4% | N/A | N/A | Nov 2, 2017 | $554.27M |
| Jun 30, 2017 | $0.67 | $0.67 | N/A | 0.00% | In line | 0.0% | N/A | N/A | Aug 3, 2017 | $546.96M |
| Mar 31, 2017 | $0.55 | $0.54 | N/A | +1.85% | Beat | -1.8% | N/A | N/A | May 4, 2017 | $514.12M |
| Dec 31, 2016 | $0.83 | $0.86 | N/A | -3.49% | Miss | -3.5% | N/A | N/A | Mar 31, 2017 | $566.77M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $5.07, up 3.5% from the year before. It was $2.74 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $5.07 | +3.5% |
| Dec 31, 2024 | $4.90 | +5.4% |
| Dec 31, 2023 | $4.65 | -41.4% |
| Dec 31, 2022 | $7.94 | -30.5% |
| Dec 31, 2021 | $11.42 | +37.8% |
| Dec 31, 2020 | $8.29 | +102.2% |
| Dec 31, 2019 | $4.10 | +13.3% |
| Dec 31, 2018 | $3.62 | +24.0% |
| Dec 31, 2017 | $2.92 | +6.6% |
| Dec 31, 2016 | $2.74 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,000 words across 14 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,039 | 14 | |
| 2026Q2 | Jun 30, 2026 | 7,749 | 11 | |
| 2026Q1 | Mar 31, 2026 | 8,098 | 11 | |
| 2025Q4 | Dec 31, 2025 | 9,216 | 14 | |
| 2025Q3 | Sep 30, 2025 | 8,746 | 14 | |
| 2025Q2 | Jun 30, 2025 | 8,340 | 14 | |
| 2025Q1 | Mar 31, 2025 | 9,641 | 13 | |
| 2024Q4 | Dec 31, 2024 | 9,225 | 14 |
2026Q3 Earnings Call
Opening remarks
Stephen Barr Willoughby SVP, Investor Relations Thank you, operator. Good morning, everyone, and welcome to Revvity's Third Quarter 2026 Earnings Conference Call. On the call with me today are Prahlad R. Singh, our President and Chief Executive Officer, and Maxwell Krakowiak, our senior vice president and chief financial officer. Before we begin, I would like to remind you that today's call may include forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from our expectations. Please refer to the Safe Harbor statements in our earnings release and to our SEC filings for a detailed discussion of these risk factors. We assume no obligation to update these forward-looking statements in the future. Additionally, we will refer to certain non-GAAP financial measures during this call. Reconciliations to the most directly comparable GAAP measures are available in our earnings release. I will now turn it over to our President and Chief Executive Officer, Prahlad R. Singh. Prahlad?
Prahlad R. Singh President and Chief Executive Officer Thank you, Steve, and good morning, everyone. I am pleased to report that Revvity delivered exceptionally strong performance in the third quarter, with pro forma organic growth of 7%, exceeding our mid-single-digit expectation. With healthy gross margins combined with sales leverage from the revenue upside we experienced, our strong incremental margins shone through, leading to pro forma adjusted operating margins in the quarter of 29.4%. This resulted in pro forma adjusted earnings per share of $1.37 for the quarter, which was $0.08 above the midpoint of our expectations. Our stronger-than-expected performance in the quarter was driven by our life sciences segment, which grew 9% organically, with reagents up high single digits, instruments up strong mid-single digits, and our Signals software business growing in the upper teens. This fantastic performance was complemented by solid performance in our diagnostics segment, which grew in the mid-single digits, in line with our expectations. As we have been sharing with you for the last several quarters, underlying market demand trends from our pharma and biotech customers continued to improve in the third quarter, following the policy-related headwinds our industry faced throughout much of last year. On top of this market recovery, we also continued to see incremental AI-related demand build and begin to expand beyond just our high-content screening business, where it was initially concentrated. While our high-content screening revenue growth continued to accelerate in the quarter, despite strong year-ago comps, our backlog for these instruments also continued to increase. We have taken additional actions to further expand our capacity in this area to support this elevated demand, while also building some additional capacity should it accelerate even more as we head into next year.
Frequently Asked Questions About RVTY
When is Revvity's next earnings date?
Revvity's next earnings report is expected for Feb 1, 2027.
Did RVTY beat earnings estimates last quarter?
Yes. Revvity reported EPS of $1.38 for the quarter ended Sep 30, 2026, above the $1.29 estimate, a 6.98% surprise.
What EPS do analysts expect from RVTY next quarter?
The consensus EPS estimate for Revvity for the quarter ending Dec 31, 2026 is $1.65 from 20 analysts, with estimates from $1.56 to $1.88.
How often does RVTY beat earnings estimates?
Revvity beat the EPS estimate in each of the last 12 quarters, with an average surprise of +7.05%.
RVTY pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts